Clinical Trial: HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    US Fed News (USA), December 13, 2024, 2pp
  • Additional Information
    • Abstract:
      U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06731504) titled 'HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT' on Dec. 09. Brief Summary: This study is a single-center, non-randomized, single-arm pilot trial of omidubicel hematopoietic stem cell transplantation (HCT) for hematologic malignancies with myeloablative conditioning chemotherapy of physician's choice followed by abatacept/tacrolimus/mycophenolate mofetil (ABA/Tac/MMF) graft-versus-host disease (GVHD) prophylaxis...